Physician profile
Larry W Mann
NPI 1497133714
$4,662.11
in general payments reported to CMS, 2019-2025
31 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $72.82 · 2021: $495 · 2022: $395 · 2023: $1,566 · 2024: $1,655 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,459.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $496.32 | 2019-2024 | |
| Abbvie INC. | $404.57 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $274.73 | 2021-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.05 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $224.77 | 2023-2024 | Rexulti |
| Amgen INC. | $211.32 | 2019-2024 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $205.66 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Lilly USA, LLC | $192.00 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $123.19 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $99.71 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $86.27 | 2021 | |
| Astellas Pharma US INC | $84.52 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $78.68 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $58.50 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.03 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $37.45 | 2024 | Voquezna |
| Exact Sciences Corporation | $36.77 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $29.68 | 2023 | |
| Fortovia Therapeutics, INC. | $29.31 | 2019 | |
| Phadia US INC. | $29.07 | 2021-2024 | Immunocap |
| Genentech USA, INC. | $28.96 | 2024 | Xolair |
| Insulet Corporation | $23.31 | 2023 | Omnipod |
| Abbott Laboratories | $22.48 | 2023 | Freestyle Libre 3 |
| Organon LLC | $19.95 | 2023 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $19.86 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $18.72 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.51 | 2022 | |
| Dynavax Technologies Corporation | $14.90 | 2024 | Heplisav-B |
| Bioventus LLC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.